922 results on '"Kawaoka, Yoshihiro"'
Search Results
2. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays
3. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses
4. A compendium of multi-omics data illuminating host responses to lethal human virus infections
5. Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging
6. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters
7. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge
8. Assessment of the antigenic evolution of a clade 6B.1 human H1N1pdm influenza virus revealed differences between ferret and human convalescent sera
9. Receptor-Binding Specificity of Influenza Viruses
10. Avian H6 Influenza Viruses in Vietnamese Live Bird Markets during 2018–2021
11. Neutrophil adhesion to vessel walls impairs pulmonary circulation in COVID-19 pathology
12. Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV
13. An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants
14. Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan
15. Neutralizing Immunity Against Antigenically Advanced Omicron BA.5 in Children After SARS-CoV-2 Infection
16. Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the virion membrane
17. Defining Distinct RNA-Protein Interactomes of SARS-CoV-2 Genomic and Subgenomic RNAs
18. 446. Post-Acute Sequelae of COVID-19 in a Rural Wisconsin Community Prospective Cohort
19. Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine
20. Cardiomyopathy Does Not Exacerbate the Severity of Pneumonia Caused by a SARS-CoV-2 Delta Variant in the J2N-k Hamster Model
21. Characterization of highly pathogenic clade 2.3.4.4b H5N1 mink influenza viruses
22. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
23. Mapping SARS-CoV-2 antigenic relationships and serological responses
24. Glyco-engineered MDCK cells display preferred receptors of H3N2 influenza absent in eggs used for vaccines
25. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
26. Host range, transmissibility and antigenicity of a pangolin coronavirus
27. Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2
28. Characterization of an EG.5.1 clinical isolate in vitro and in vivo
29. The New Anti-influenza Drug Baloxavir Marboxil: Can Influenza Viruses with Reduced Susceptibility to Baloxavir Maintain Viral Fitness?
30. Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging
31. Development of an Enhanced High-Yield Influenza Vaccine Backbone in Embryonated Chicken Eggs
32. Ebola Virus Infection Induces HCAR2 Expression Leading to Cell Death
33. An antiviral role for TRIM14 in Ebola virus infection
34. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes
35. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
36. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
37. Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
38. Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
39. Broad Protection Against Clade 1 Sarbecoviruses After a Single Immunization with Cocktail Spike-Protein-Nanoparticle Vaccine
40. Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants
41. Efficacy of favipiravir against influenza virus resistant to both baloxavir and neuraminidase inhibitors
42. Defining distinct RNA-protein interactomes of SARS-CoV-2 genomic and subgenomic RNAs
43. Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents
44. Sensitivity of rapid antigen tests for Omicron subvariants of SARS‐CoV‐2
45. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
46. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
47. Highly Pathogenic H5 Influenza Viruses Isolated between 2016 and 2017 in Vietnamese Live Bird Markets
48. Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants
49. Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
50. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.